Ironwood Pharmaceuticals, a commercial biotech company, announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and “R&D Co.”). The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders. Following the separation, Ironwood anticipates…
Allergan And Ironwood Settle Linzess Patent Suit With Sun Pharma
Ironwood Pharmaceuticals, Inc. and Allergan plc have reached an agreement with wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd. resolving patent litigation brought in response to Sun Pharma’s abbreviated new drug application (ANDA) seeking approval to market a generic version of Linzess (linaclotide) prior to the expiration of the companies’ applicable patents. Pursuant to the terms of the settlement,…